Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

KOS-862 enters phase Ib trial in combination with Paraplatin for solid tumors

July 29, 2004

Enrollment completed in STELLAR 2 trial of Xyotax

July 29, 2004

Novel propapoptotic agents newly developed at Aponetics

July 29, 2004

Novartis presents new VEGF inhibitors for cancer and ocular disorders

July 29, 2004

Merck researchers claim new tyrosine kinase regulators and their use

July 29, 2004

Promising antitumor activity reported for DRF-1042 in patients with refractory solid tumors

July 28, 2004

PBI-1402: a hematopoietic growth stimulant and chemoprotective agent

July 28, 2004

Korean team describes antitumor agents targeting Wnt-signaling pathways

July 28, 2004

Novel protein kinase inhibitors and their use in cancer therapy

July 27, 2004

DMAG enters phase I

July 26, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...